ETF1P1

Across TCGA pan-cancer cohorts, ETF1P1 RNA differs between tumor and matched normal tissue in 5 of 18 cancer types tested, making tumor–normal expression one of ETF1P1’s most consistent transcriptional readouts.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where ETF1P1 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types ETF1P1 is over-expressed in tumor, although a few such as ESCA show the opposite, repressed pattern.

LIHC, KIRC, and STAD are the cancer types where ETF1P1 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in ETF1P1 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
LIHC	All	III,IV	+0.068	.004	6	view →
KIRC	All	II,III,IV	+0.053	.006	4	view →
STAD	All	All	+0.133	.029	2	view →
COAD	All	All	+0.092	.034	2	view →
ESCA	Female	All	−0.430	.043	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 5 strongest of 5 lineages.

ETF1P1–LIHC

Open the LIHC breakdown →